313 research outputs found
Improved version of a silicon telescope system for measurements of charged multiplicity variations
No full textMammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung
No full textAmong alternative therapeutic strategies in clinically aggressive neuroendocrine tumors (NETs) of the lung, promising results have been obtained in experimental clinical trials with mammalian target of rapamycin (mTOR) inhibitors, though in the absence of a proven mTOR signaling activation status. This study analyzed the expression of phosphorylated mTOR (p-mTOR) and its major targets, the ribosomal p70S6-kinase (S6K) and the eukaryotic initiation factor 4E-binding protein 1 (4EBP1) in a large series of 218 surgically resected, malignant lung NETs, including 24 metastasizing typical carcinoids, 73 atypical carcinoids, 60 large cell neuroendocrine carcinomas (LCNECs), and 61 small cell carcinomas (SCLCs). By immunohistochemistry, low-to-intermediate-grade tumors as compared with high-grade tumors showed higher levels of p-mTOR and phosphorylated S6K (p-S6K) (P<0.001), at variance with phosphorylated 4EBP1 (p-4EBP1), which was mainly expressed in LCNECs and SCLCs (P<0.001). The activated status of mTOR pathway was proved by the strong correlation of p-mTOR with p-S6K and somatostatin receptor(s). Western blot analysis of NET tumor samples confirmed such findings, and differential sensitivity to mTOR inhibition according to mTOR pathway activation characteristics was determined in two lung carcinoid cell lines in vitro. None of the investigated molecules had an impact on survival. However, in low-grade tumors, low p-mTOR expression correlated with lymph node metastases (P=0.016), recurrent disease, and survival (P=0.005). In conclusion, these data demonstrate a differential mTOR activation status in the spectrum of pulmonary NETs, possibly suggesting that mTOR pathway profiling might play a predictive role in candidate patients for mTOR-targeted therapies
Pilomatrix-like High-grade Endometrioid Carcinoma is a Morphologically and Immunophenotypically Distinct Entity and May Show Mismatch Repair Deficiency
No full textPrognostic predictors in recurrent adult granulosa cell tumors of the ovary: a systematic review and meta-analysis
No full textBackground: Ovarian adult granulosa cell tumours are low-grade malignant sex cord–stromal neoplasm with a low recurrence rate. Prognostic factors for recurrence include tumor stage, tumor rupture in Stage I neoplasms and the presence of residual tumors after surgery. However, in recurrent tumors, prognostic factors for overall survival (OS) are lacking. In the present paper, we conducted a systematic meta-analysis with the aim to assess prognostic factors for OS in patients with recurrent GCT. Methods: Electronic databases were searched for all studies assessing prognostic factors in recurrent adult granulosa cell tumor of the ovary. Student T test, Fisher’s exact test and Kaplan–Meier survival analysis with long-rank test were used to assess differences among groups; a p value < 0.05 was considered significant. Results: Eleven studies analyzing 102 recurrent tumors were included in the systematic review. Tumor stage and localization of recurrent tumors were significantly associated with OS on Kaplan–Meier analysis; Cox regression analysis showed a HR of 0.879 for the stage II, of 3.052 for the stage III, and of 2.734 for stage IV tumor was significantly associated with OS (p = 0.037); observed HRs for abdominal and thoracic locations were of 2.405 and of 4.024, respectively. Conclusions: In conclusion, the present article emphasizes the prognostic significance of tumor stage > II and extrapelvic anatomic sites of recurrences in patients with recurrent granuolase cell tumors of the ovary
Is 18F-fluorodeoxyglucose the tracer of choice for functional imaging of neuroendocrine tumors grade 3? A case report
No full textN/
Bronchogenic cyst. Unexpected finding in a large aneurysm of the pars membranacea septi
No full textIntracardiac bronchogenic cysts are rare, with only 5 cases
reported to date: 2 in the atrial septum, 1 in the left atrium,
and 2 in the right ventricle. They are identified by asymptomatic occasional findings or nonspecific symptoms, mostly in
the second to fourth decades.
Bronchogenic cysts are believed to represent a localized portion
of the tracheobronchial tree that separates from the normal
airways during the branching process and does not undergo
further development. They develop between the 26th and the
40th day of intrauterine life, during the most active period of
airway development. The timing of the abnormal budding may
determine the location: earlier in the mediastinum and later within
lung tissue, which are the 2 most common locations. Intracardiac
location can be explained with a more precocious abnormal budding, approximately 21 days after fertilization, when the cardiac primordial tube is near the foregut or primitive tracheobronchial tree.
Other noncardiac, atypical locations are cutaneous, retroperitoneal, cervical, intradiaphragmatic, intrapericardial, intraspinal, and intrapleural.
We report a case of a bronchogenic cyst located in the wall of
a large aneurysm of the pars membranacea septi triggering premature ventricular complex (PVC) and sinus tachycardia
- …
